The immune system has long been recognised important in pain regulation through inflammatory cytokine modulation of peripheral nociceptive fibres. Recently, cytokine interactions in brain and spinal cord glia as well as dorsal root ganglia satellite glia have been identified important- in pain modulation. The result of these interactions is central and peripheral sensitisation of nociceptive processing. Additionally, new insights and the term 'autoimmune pain' have emerged through discovery of specific IgGs targeting the extracellular domains of antigens at nodal and synaptic structures, causing pain directly without inflammation by enhancing neuronal excitability. Other discovered IgGs heighten pain indirectly by T-cell-mediated inflammation or destruction of targets within the nociceptive pathways. Notable identified IgGs in pain include those against the components of channels and receptors involved in inhibitory or excitatory somatosensory synapses or their pathways: nodal and paranodal proteins (LGI1, CASPR1, CASPR2); glutamate detection (AMPA-R); GABA regulation and release (GAD65, amphiphysin); glycine receptors (GLY-R); water channels (AQP4). These disorders have other neurological manifestations of central/peripheral hyperexcitabability including seizures, encephalopathy, myoclonus, tremor and spasticity, with immunotherapy responsiveness. Other pain disorders, like complex regional pain disorder, have been associated with IgGs against β2-adrenergic receptor, muscarinic-2 receptors, AChR-nicotinic ganglionic α-3 receptors and calcium channels (N and P/Q types), but less consistently with immune treatment response. Here, we outline how the immune system contributes to development and regulation of pain, review specific IgG-mediated pain disorders and summarise recent development in therapy approaches. Biological agents to treat pain (anti-calcitonin gene-related peptide and anti-nerve growth factor) are also discussed.
Keywords: autoimmune; chronic; pain.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: DLHB reports that he has acted as a consultant on behalf of Oxford Innovation for Abide, Biogen, GSK, Lilly, Mitsubishi Tanabe, Mundipharma and TEVA over the last 3 years. LAQ reports that he has provided expert testimony for Grifols and CSL Behring and received research funds from Novartis Spain and Grifols. SRI reports that he is a coapplicant and receives royalties on patent application WO/2010/046716 (UK patent no. PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies. The remaining authors report no relevant disclosures to this work.
[Pathophysiology of low back pain and the transition to the chronic state - experimental data and new concepts].Schmerz. 2001 Dec;15(6):413-7. doi: 10.1007/s004820100002. Schmerz. 2001. PMID: 11793144 German.
Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.J Neural Transm (Vienna). 2014 Aug;121(8):1029-75. doi: 10.1007/s00702-014-1193-3. Epub 2014 Aug 1. J Neural Transm (Vienna). 2014. PMID: 25081016 Review.
Perspectives in Pain Research 2014: Neuroinflammation and glial cell activation: The cause of transition from acute to chronic pain?Scand J Pain. 2015 Jan 1;6(1):3-6. doi: 10.1016/j.sjpain.2014.10.002. Scand J Pain. 2015. PMID: 29911589
Inhibition Mediated by Glycinergic and GABAergic Receptors on Excitatory Neurons in Mouse Superficial Dorsal Horn Is Location-Specific but Modified by Inflammation.J Neurosci. 2017 Mar 1;37(9):2336-2348. doi: 10.1523/JNEUROSCI.2354-16.2017. Epub 2017 Jan 27. J Neurosci. 2017. PMID: 28130358 Free PMC article.
The immunobiology of autoimmune encephalitides.J Autoimmun. 2019 Nov;104:102339. doi: 10.1016/j.jaut.2019.102339. Epub 2019 Oct 11. J Autoimmun. 2019. PMID: 31611142 Review.
Cited by 3 articles
Novel Neuropathic Pain Mechanisms Associated With Allergic Inflammation.Front Neurol. 2019 Dec 17;10:1337. doi: 10.3389/fneur.2019.01337. eCollection 2019. Front Neurol. 2019. PMID: 31920952 Free PMC article. Review.
Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia - a randomized controlled trial.BMC Anesthesiol. 2019 Dec 19;19(1):236. doi: 10.1186/s12871-019-0912-6. BMC Anesthesiol. 2019. PMID: 31856760 Free PMC article.
Structural homology of myelin basic protein and muscarinic acetylcholine receptor: Significance in the pathogenesis of complex regional pain syndrome.Mol Pain. 2018 Jan-Dec;14:1744806918815005. doi: 10.1177/1744806918815005. Epub 2018 Nov 5. Mol Pain. 2018. PMID: 30392459 Free PMC article. Review.